This Pearl is provided as free content. Here is the link to our terms of use
Alpha-gal syndrome: tick-borne allergy to red meat
Alpha-gal syndrome: tick-borne allergy to red meat
Alpha-gal syndrome is an allergic response to mammalian proteins, triggered by repeated tick bites. It has been rapidly increasing in prevalence in the US since 2009, but is new to the UK. It is named after galactose-alpha 1,3-galactose, which is an oligosaccharide.
Although rare in this country, it has potentially life-threatening consequences and an unusual pattern of delayed anaphylaxis. This article highlights the key facts using a BJGP Clinical Practice article alongside information taken from the CDC (BJGP 2025;75(753):186, CDC - about alpha-gal syndrome).
This article was updated in October 2025.
You may find it helpful to read this alongside our articles on Lyme disease: NICE guideline and Tick-borne encephalitis.
|
Headlines |
What is alpha-gal syndrome?
Alpha-gal syndrome is a serious IgE-mediated allergic response, usually to red meat, but it can also occur in response to other related products, including medications. It is the first known allergy where a carbohydrate is the source of an IgE-mediated response.
When a tick latches on and prepares to ingest a blood meal, it first has to inject a small amount of its saliva, containing an anticoagulant made from alpha-gal glycoproteins, to enable it to feed. This is the moment at which infection with Lyme disease or tick-borne encephalitis carried within the saliva can occur.
In people with genetic susceptibility, the alpha-gal glycoprotein can trigger a sensitisation response, and repeated exposure can then lead to an IgE-mediated immune response (type-1 hypersensitivity).
It was previously thought that only the lone-star tick (confined to the US) was associated with the syndrome, but it is now known that the UK tick species Ixodes ricinus is causing red meat food allergy in UK residents (BJGP 2025;75(753):186).
Prevalence
There have been 16 confirmed cases of UK-triggered alpha-gal syndrome since 2021 (all in Scotland) (BJGP 2025;75(753):186). Annual incidence is 0.38/100 000 people.
In the US, there have been more than 110 000 suspected cases in the past decade (CDC - about alpha-gal syndrome). However, because cases are difficult to identify and there is no formal reporting requirement, the CDC comments that this is likely to be an underestimate.
In Scotland, the confirmed cases mirror geographical patterns of Lyme disease (BJGP 2025;75(753):186). It is likely that the same will be true in England and Wales.
We should consider alpha-gal syndrome in people with relevant symptoms who have spent time in the countryside in:
- Scotland (especially Fife, the Highlands and Tayside).
- The New Forest.
- Dartmoor.
- Exmoor.
- Thetford.
- Cumbria.
Presentation
IgE-mediated allergic responses (including anaphylaxis) typically occur very rapidly after contact with the trigger (within 30 minutes).
In alpha-gal syndrome, although it is an IgE-mediated reaction, symptoms usually occur 2–6h after contact with the trigger (BJGP 2025;75(753):186). The delayed presentation is thought to be because digestion of the meat product is required before the alpha-gal oligosaccharide is released into the small bowel, triggering the immune response.
Symptoms include (CDC - symptoms of alpha-gal syndrome):
- Urticaria.
- Gastro-intestinal symptoms: nausea, vomiting, stomach pain, indigestion, diarrhoea.
- Angioedema.
- Respiratory symptoms, including cough and wheeze.
- Hypotension.
- Dizziness/faintness.
- Anaphylaxis can occur.
As a patient becomes more sensitised to repeat exposure, the allergic reaction can become more severe and occur more rapidly (BJGP 2025;75(753):186).
Triggers
Alpha-gal is a carbohydrate found on the surface of the cells of most non-primate mammals.
| Triggers | |||
| Food | Medication | Co-factors | |
| High risk |
|
|
Factors shown to increase the risk or severity of a reaction: |
| Medium risk | |||
| Low risk |
|
||
| (CDC - products that may contain alpha-gal, BJGP 2025;75(753):186, Anaphylaxis UK - alpha-gal allergy) | |||
Investigation and management
If we suspect alpha-gal syndrome, we should check alpha-gal-specific IgE serology to confirm.
Patients with suspected alpha-gal syndrome should be referred to an allergy specialist to confirm the diagnosis and identify which triggers need to be avoided (gov.uk - alpha-gal syndrome).
Management is by avoidance of tick bites, avoidance of triggers, and use of adrenaline auto-injectors and antihistamines.
Patients may need specific dietetic device to support them in this. Anaphylaxis UK has produced a patient information leaflet with more details: Anaphylaxis UK - alpha-gal allergy.
There is evidence of IgE cross-reactivity between alpha-gal and wasp venom. People who have alpha-gal syndrome are more likely to also be sensitive to wasp venom (CTA 2022;12:e12113).
Tick bite avoidance
(UKHSA - tips and tricks to stay safe from ticks, accessed April 2025)
We should give good advice about bite avoidance:
- Dawn-to-dusk protection.
- Long sleeves/trousers.
- Adequate use of insect repellent.
Tick removal
After walking/hiking:
- Check the body for ticks.
- Remove ticks using fine-toothed tweezers/tick remover (see article on Lyme disease: NICE guideline to learn how to do this).
![]() |
Alpha-gal syndrome: tick-borne allergy to red meat |
![]() |
Useful resources for patients: Websites (all resources are hyperlinked for ease of use in Red Whale Knowledge) |
This information is for use by clinicians for individual educational purposes, and should be used only within the context of the scope of your personal practice. It should not be shared or used for commercial purposes. If you wish to use our content for group or commercial purposes, you must contact us at sales@red-whale.co.uk to discuss licensing, otherwise you may be infringing our intellectual property rights.
Although we make reasonable efforts to update and check the information in our content is accurate at the date of publication or presentation, we make no representations, warranties or guarantees, whether express or implied, that the information in our products is accurate, complete or up to date.
This content is, of necessity, of a brief and general nature, and this should not replace your own good clinical judgment or be regarded as a substitute for taking professional advice in appropriate circumstances. In particular, check drug doses, side effects and interactions with the British National Formulary. Save insofar as any such liability cannot be excluded at law, we do not accept any liability for loss of any type caused by reliance on the information in these pages.
Here is the link to our terms of use.

